RT Journal Article
SR Electronic
T1 T cell anergy in COVID-19 reflects virus persistence and poor outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.21.20198671
DO 10.1101/2020.09.21.20198671
A1 Renner, Kerstin
A1 Müller, Christine
A1 Tiefenböck, Charlotte
A1 Salewski, Jan-Niklas
A1 Winter, Frederike
A1 Buchtler, Simone
A1 Malfertheiner, Maximilian V.
A1 Lubnow, Matthias
A1 Lunz, Dirk
A1 Graf, Bernhard
A1 Hitzenbichler, Florian
A1 Hanses, Frank
A1 Poeck, Hendrik
A1 Kreutz, Marina
A1 Orsó, Evelyn
A1 Burkhardt, Ralph
A1 Niedermair, Tanja
A1 Brochhausen, Christoph
A1 Gessner, André
A1 Salzberger, Bernd
A1 Mack, Matthias
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.21.20198671.abstract
AB Coronavirus disease 2019 (COVID-19) can lead to severe pneumonia and hyperinflammation. So far, insufficient or excessive T cell responses were described in patients. We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery. T cell activation was measured by downstream effects on responder cells like basophils, plasmacytoid dendritic cells, monocytes and neutrophils in whole blood and proved to be much more meaningful than classical readouts with PBMCs. Monocytes responded stronger in males than females and IL-2 partially reversed T cell anergy. Downstream markers of T cell anergy were also found in fresh blood samples of critically ill patients with severe T cell anergy. Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Bavarian Ministry of Science and Arts.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee from the University Hospital Regensburg (Study and Approval Number: 20-1785-101)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.